Latest news with #CompassTherapeutics
Yahoo
3 days ago
- Business
- Yahoo
Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the top high-return penny stocks to buy now. On July 14, Stifel reiterated its Buy rating and $11.00 price target for CMPX. The firm views the extended timeline for topline data from the Phase 2/3 COMPANION-002 trial—now expected in Q4 2025—as a positive, given the 19-month follow-up in a cancer type with typically short survival rates. A research team in lab coats testing a new ImmunoPhage platform in a modern biotechnology lab. Beyond COMPANION-002, Stifel highlighted two upcoming 2025 catalysts: Phase 1 results for CTX-8371, a PD-1xPD-L1 bispecific antibody, and preclinical data on CTX-10726 targeting PD-1 and VEGF-A. Interest is also growing around CTX-837's unique multi-modal mechanism, reinforcing Compass's innovation in immuno-oncology. Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage biotech company developing antibody-based cancer treatments in the U.S. Its lead candidates include bispecific antibodies like tovecimig (targeting DLL4 and VEGF-A), CTX-471 (stimulating CD137 for immune activation), and CTX-8371 (blocking PD-1/PD-L1). The company also advances CTX-10726 and VEGF-focused bispecifics aimed at enhancing anti-tumor immunity and inhibiting angiogenesis. While we acknowledge the potential of CMPX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
15-07-2025
- Business
- Business Insider
Compass Therapeutics (CMPX) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Stephen Willey reiterated a Buy rating on Compass Therapeutics today and set a price target of $11.00. The company's shares opened today at $2.66. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Willey covers the Healthcare sector, focusing on stocks such as Incyte, Bicara Therapeutics Inc., and Exelixis. According to TipRanks, Willey has an average return of 2.0% and a 40.34% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Compass Therapeutics with a $13.20 average price target, which is a 396.24% upside from current levels. In a report released on July 1, Raymond James also initiated coverage with a Buy rating on the stock with a $9.00 price target. CMPX market cap is currently $373.4M and has a P/E ratio of -6.74. Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CMPX in relation to earlier this year. Most recently, in May 2025, Thomas Schuetz, the CEO of CMPX bought 10,000.00 shares for a total of $21,100.00.
Yahoo
14-05-2025
- Business
- Yahoo
Spotlight On Three Promising Penny Stocks In May 2025
As the U.S. market rallies with tech stocks leading gains, investors are increasingly optimistic about the potential for continued growth. Penny stocks, a term that may seem outdated, still represent an intriguing investment area for those interested in smaller or newer companies. By focusing on penny stocks with strong financial health and clear growth potential, investors can uncover opportunities that offer both stability and upside. Name Share Price Market Cap Financial Health Rating Safe Bulkers (NYSE:SB) $3.61 $372.2M ★★★★☆☆ IDenta (OTCPK:IDTA) $0.75 $3.03M ★★★★★★ Tuya (NYSE:TUYA) $2.71 $1.54B ★★★★★★ WM Technology (NasdaqGS:MAPS) $1.14 $188.36M ★★★★★★ Flexible Solutions International (NYSEAM:FSI) $4.44 $56.66M ★★★★★★ Imperial Petroleum (NasdaqCM:IMPP) $2.66 $91.2M ★★★★★★ BAB (OTCPK:BABB) $0.84 $5.96M ★★★★★★ Dingdong (Cayman) (NYSE:DDL) $2.37 $518.62M ★★★★★★ Lifetime Brands (NasdaqGS:LCUT) $3.315 $81.59M ★★★★★☆ CBAK Energy Technology (NasdaqCM:CBAT) $0.935 $81.31M ★★★★★☆ Click here to see the full list of 756 stocks from our US Penny Stocks screener. We'll examine a selection from our screener results. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based therapeutics for treating various human diseases, with a market cap of $277.95 million. Operations: Compass Therapeutics, Inc. currently does not report any revenue segments. Market Cap: $277.95M Compass Therapeutics, Inc., with a market cap of US$277.95 million, is a pre-revenue biopharmaceutical company focused on antibody-based therapeutics. Despite its unprofitability and negative return on equity of -50.07%, the company maintains a strong balance sheet with short-term assets exceeding liabilities and no debt. Recent developments include promising clinical trial results for tovecimig in biliary tract cancer (BTC), showing significant improvement in overall response rate when combined with paclitaxel compared to paclitaxel alone. However, high volatility remains a concern, as does the relatively inexperienced management team with an average tenure of 1.8 years. Click here and access our complete financial health analysis report to understand the dynamics of Compass Therapeutics. Assess Compass Therapeutics' future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Village Farms International, Inc. operates in North America producing, marketing, and distributing greenhouse-grown tomatoes, bell peppers, cucumbers, and mini-cukes with a market cap of $78.98 million. Operations: Village Farms International does not report specific revenue segments. Market Cap: $78.98M Village Farms International, with a market cap of US$78.98 million, operates in the greenhouse-grown produce sector and is currently unprofitable with increasing losses over five years. Despite this, the company has reduced its debt-to-equity ratio and maintains a satisfactory net debt level. Recent refinancing efforts have improved financial covenants on its cannabis credit facility, extending maturity to 2028. The company faces delisting risks from Nasdaq due to non-compliance with bid price requirements but has received an extension until October 2025 to rectify this issue. Revenue growth is expected at 13.62% annually, though profitability remains elusive in the near term. Dive into the specifics of Village Farms International here with our thorough balance sheet health report. Examine Village Farms International's earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★★★ Overview: RPC, Inc. provides a variety of oilfield services and equipment to oil and gas companies engaged in exploration, production, and development activities, with a market cap of approximately $1.08 billion. Operations: RPC's revenue is primarily derived from its Technical Services segment, which accounts for $1.28 billion, complemented by its Support Services segment contributing $88.59 million. Market Cap: $1.08B RPC, Inc., with a market cap of US$1.08 billion, operates in the oilfield services sector and has shown profitability growth over the past five years. Despite recent challenges, including a decline in sales to US$332.88 million for Q1 2025 from US$377.83 million a year ago, RPC maintains no debt and strong short-term assets exceeding liabilities. The company is exploring acquisitions to leverage its robust balance sheet and liquidity amidst industry volatility. Although its profit margins have decreased, RPC's price-to-earnings ratio suggests it may be undervalued compared to the broader U.S. market average of 17.9x. Take a closer look at RPC's potential here in our financial health report. Gain insights into RPC's future direction by reviewing our growth report. Click through to start exploring the rest of the 753 US Penny Stocks now. Contemplating Other Strategies? The latest GPUs need a type of rare earth metal called Terbium and there are only 23 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:CMPX NasdaqCM:VFF and NYSE:RES. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
06-05-2025
- Business
- Yahoo
Compass Therapeutics to Participate in Upcoming May Investor Events
Compass Therapeutics BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: The Citizens Life Sciences Conference Location: New York, NY Date: Thursday, May 8, 2025 Time: 1:30 PM ET Webcast Link: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ Location: New York, NY Date: Tuesday, May 20, 2025 Time: 11:30AM ET Webcast Link: Virtual/Replay availability: Presentations will be archived for 90 days on Compass' Events page. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at Investor Contact ir@ Media Contact Anna Gifford, Chief of Staff media@ 617-500-8099
Associated Press
28-04-2025
- Business
- Associated Press
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled 'Enhanced Efficacy of CTX-471, A CD137 Agonist Antibody, In Models of Immune Checkpoint Failure Via Simultaneous Blockade of Neo-Angiogenesis' at the American Association for Cancer Research (AACR) Annual Meeting, from April 25–30, 2025, at the McCormick Place Convention Center in Chicago, IL. 'We are encouraged by the preclinical data shared at AACR, which demonstrated increases in the tumoral immune infiltrate in several mouse models following CTX-471 monotherapy,' said Thomas Schuetz, M.D., Ph.D., Chief Executive Officer and Scientific Founder of Compass. 'Our results also suggest that combining CTX-471 with a next-generation anti-angiogenic agent such as tovecimig might not only enhance therapeutic efficacy and duration of response to CTX-471, but may also provide clinical benefit to patients in whom checkpoint inhibitors have failed. We look forward to advancing our ongoing work in these programs, with potential application across multiple solid tumor types and patient populations.' Tovecimig in combination with CTX-471 demonstrated compelling activity in multiple murine models, including novel models highly resistant to immune checkpoint inhibitors: The combination of CTX-471 with tovecimig was effective in these mouse models where conventional immune checkpoint inhibitors show reduced activity. Mechanistically, the combination appears to enhance inflammasome activation, pyroptosis, and interferon-mediated signaling, potentially providing clinical benefit to patients in whom checkpoint inhibitors have failed. A copy of the presentation materials can be accessed on the News & Events section under ' Presentations ' of the Company's website at once the presentation has concluded. About CTX-471 CTX-471 is a fully human monoclonal antibody that binds and activates a novel epitope of the co-stimulatory receptor CD137, also known as 4-1BB, a member of the tumor necrosis factor receptor superfamily. The antibody is currently being evaluated in a Phase 1b clinical trial in patients with solid tumors that have progressed after at least three months on an approved PD-1 or PD-L1 inhibitor. Initial results reported from a monotherapy cohort of the study included partial responses in melanoma, small cell lung cancer, and mesothelioma, and CTX-471 has been generally well tolerated. In preclinical studies, CTX-471 has demonstrated potent monotherapy activity against multiple syngeneic tumor models, including the generation of long-term functional immunological memory. About Tovecimig (CTX-009) Tovecimig is an investigational bispecific antibody that is designed to simultaneously block Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. Preclinical and early clinical data of tovecimig suggest that blockade of both pathways provides robust anti-tumor activity across several solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic and non-small cell lung cancer. Partial responses to tovecimig as a monotherapy have been observed in heavily pre-treated patients with cancer who were resistant to approved anti-VEGF therapies. COMPANION-002, a Phase 2/3 trial of tovecimig plus paclitaxel versus paclitaxel monotherapy in patients with previously treated, unresectable advanced metastatic or recurrent biliary tract cancers (BTC) is ongoing (clinical trial information: NCT05506943 ). About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The Company's pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding Compass's product candidates, including the therapeutic potential of tovecimig and CTX-471. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass's ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass's ability to identify additional product candidates for development, Compass's ability to develop, complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the U.S. Securities and Exchange Commission (SEC) available at including without limitation Compass's latest Annual Report on Form 10-K and subsequent filings with the SEC. Investor Contact [email protected] Media Contact Anna Gifford, Senior Communications Manager [email protected] 617-500-8099
